Content about Aventis

November 8, 2013

Sanofi-Aventis has sued the Food and Drug Administration to keep its labeling for OTC Nasacort confidential in an effort to delay store brand competition until after the launch, according to an entry in the FDA Law Blog, the official blog of Hyman, Phelps & McNamara, published Thursday.

WASHINGTON — Sanofi-Aventis has sued the Food and Drug Administration to keep its labeling for OTC Nasacort confidential in an effort to delay store brand competition until after the launch, according to an entry in the FDA Law Blog, the official blog of Hyman, Phelps & McNamara, published Thursday. 

August 10, 2011

Sanofi on Wednesday announced the introduction of Allegra's new Allergy Adventures contest on Facebook. Allergy sufferers are invited to upload a short video showing their daily challenges with allergies for a chance to win $5,000 toward a vacation package.

BRIDGEWATER, N.J. — Sanofi on Wednesday announced the introduction of Allegra's new Allergy Adventures contest on Facebook. Allergy sufferers are invited to upload a short video showing their daily challenges with allergies for a chance to win $5,000 toward a vacation package.

July 20, 2011

Canadian drug maker Valeant Pharmaceuticals International has signed an agreement with Sanofi’s subsidiary in Canada to distribute a topical medication for osteoarthritis in the country.

MISSISSAUGA, Ontario — Canadian drug maker Valeant Pharmaceuticals International has signed an agreement with Sanofi’s subsidiary in Canada to distribute a topical medication for osteoarthritis in the country.

Valeant said Tuesday that it had reached an agreement with Sanofi-Aventis Canada for Canadian marketing and distribution rights to Zuacta (zucapsaicin), designed for treating osteoarthritis of the knee.

May 31, 2011

New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

PARIS — New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

May 9, 2011

French drug maker Sanofi-Aventis has shortened its name to Sanofi, the company said.

PARIS — French drug maker Sanofi-Aventis has shortened its name to Sanofi, the company said.

The company, which acquired Cambridge, Mass.-based biotech giant Genzyme for $20.1 billion earlier this year, had planned to vote at its shareholder meeting Friday.

According to published reports, the previous name was difficult to pronounce for people in many countries.

April 29, 2011

Sanofi-Aventis on Thursday reported strong sales out of the gate for its recently switched second-generation antihistamine Allegra.

PARIS — Sanofi-Aventis on Thursday reported strong sales out of the gate for its recently switched second-generation antihistamine Allegra.

Allegra generated in excess of $26.7 million within its first month available as a nonprescription allergy treatment in the U.S. market, becoming No. 2 in terms of dollar share of allergy, the company reported.

First-quarter sales of Sanofi’s Consumer Health Care totaled $1.1 billion, representing an increase of 40.3%.

April 27, 2011

An investigational drug helped patients survive longer when combined with chemotherapy as a second-line treatment for colorectal cancer that had spread to other parts of the body, according to results of a late-stage clinical trial announced by French drug maker Sanofi-Aventis and U.S.-based Regeneron Pharmaceuticals.

PARIS — An investigational drug helped patients survive longer when combined with chemotherapy as a second-line treatment for colorectal cancer that had spread to other parts of the body, according to results of a late-stage clinical trial announced by French drug maker Sanofi-Aventis and U.S.-based Regeneron Pharmaceuticals.

The phase-3 trial combined the drug Zaltrap (aflibercept) with a combination of the chemotherapy drugs folinic acid (leucovorin), 5-fluorouracil and irinotecan, also known as the FOLFIRI regimen.

April 25, 2011

The Food and Drug Administration has approved the first vaccine for preventing meningococcal disease in children as young as 9 months old, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved the first vaccine for preventing meningococcal disease in children as young as 9 months old, the agency said.

The FDA announced the approval of Menactra, made by Sanofi Pasteur, the vaccines arm of French drug maker Sanofi-Aventis. Meningococcal disease is a life-threatening illness caused by Neisseria meningitidis bacteria that infect the bloodstream and the lining surrounding the brain and spinal cord.

April 25, 2011

Customers are seeing purple again — reminiscent of another switch that took advantage of the eye-catching color purple. Sanofi-Aventis through its Chattem division in March launched Allegra, the last of the second-generation antihistamines. And purple-powered displays, like this in a Walmart in Lancaster, Pa., dotted the retail pharmacy landscape.


April 12, 2011

A U.S. Department of Agriculture study published in March in the journal Proceedings of the National Academy of Sciences has found that ragweed season is almost 16 days longer than it was in 1995 due to changes in the first frost line of the fall in North America. The first frost steadily has been creeping northward and later into the year, lead researcher Lewis Ziska wrote. That’s 16 more days of allergy relief sales — especially good news for Chattem as it shepherds its recently switched Allegra antihistamine through its first year.

BELTSVILLE, Md. — A U.S. Department of Agriculture study published in March in the journal Proceedings of the National Academy of Sciences has found that ragweed season is almost 16 days longer than it was in 1995 due to changes in the first frost line of the fall in North America. The first frost steadily has been creeping northward and later into the year, lead researcher Lewis Ziska wrote.

April 11, 2011

Genzyme now officially is a wholly owned subsidiary of Sanofi-Aventis.

PARIS — Genzyme now officially is a wholly owned subsidiary of Sanofi-Aventis.

The Paris-based drug maker said that the closing followed the completion of the exchange offer for drug maker Genzyme last week. As its subsidiary, Genzyme will become a new platform in Sanofi's sustainable growth strategy and expand the company's presence in biotechnology, Sanofi said. Genzyme will continue to operate out of its Cambridge, Mass., headquarters, and will be led by Sanofi CEO Christopher Viehbacher for several months.

April 5, 2011

Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.

NEW ORLEANS — Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.

April 4, 2011

French drug maker Sanofi-Aventis may get a name change soon, according to a published report.

NEW YORK — French drug maker Sanofi-Aventis may get a name change soon, according to a published report.

Bloomberg reported that the drug maker had scheduled a vote at its May 6 stockholders meeting to shorten the name to “Sanofi.” The article paraphrased a spokesman as saying that the current name is difficult for people in some countries to pronounce.

The Sanofi-Aventis name came into being following the 2004 acquisition of Aventis by Sanofi-Synthelabo.

April 4, 2011

Sanofi-Aventis said it completed its exchange offer for drug maker Genzyme, which expired just before midnight April 1.

PARIS — Sanofi-Aventis said it completed its exchange offer for drug maker Genzyme, which expired just before midnight April 1.

All 224,528,469 shares of Genzyme common stock were validly tendered, which is represented by 84.6% of common stock and 77% of shares on a diluted basis.

Last month, the board of directors of Genzyme unanimously recommended that shareholders accept French drug maker Sanofi-Aventis’ $74-per-share buyout offer.

March 11, 2011

While failing to improve overall survival, an investigational treatment for non-small cell lung cancer made by Sanofi-Aventis and Regeneron Pharmaceuticals did keep the disease from worsening and, overall, caused patients to respond to treatment, according to results of a late-stage clinical trial.

TARRYTOWN, N.Y. — While failing to improve overall survival, an investigational treatment for non-small cell lung cancer made by Sanofi-Aventis and Regeneron Pharmaceuticals did keep the disease from worsening and, overall, caused patients to respond to treatment, according to results of a late-stage clinical trial.

Sanofi and Regeneron announced Thursday results of the phase-3 “VITAL” trial of aflibercept. Patients were administered either the drug or placebo in addition to docetaxel chemotherapy.

March 7, 2011

The board of directors of Genzyme unanimously recommended that shareholders accept French drug maker Sanofi-Aventis’ $74-per-share buyout offer, Genzyme said Monday.

CAMBRIDGE, Mass. — The board of directors of Genzyme unanimously recommended that shareholders accept French drug maker Sanofi-Aventis’ $74-per-share buyout offer, Genzyme said Monday.

Genzyme recently accepted Sanofi’s $20.1 billion offer for the Cambridge, Mass.-based biotech company. Sanofi had sought to buy the company since last July, when it offered $18.5 billion, or $69 per share.

February 18, 2011

A whole slew of drugs will lose patent protection this year, opening up opportunities for generic drug makers to market their own versions. Most notable among these is Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin), the world’s top-selling drug, with U.S. sales of $7 billion during the 12 months ended September 2010, according to IMS Health.


February 16, 2011

The National Basketball Association, the Women's National Basketball Association and the NBA Development League are at the forefront of a new campaign that seeks to raise awareness about diabetes prevention.

NEW YORK — The National Basketball Association, the Women's National Basketball Association and the NBA Development League are at the forefront of a new campaign that seeks to raise awareness about diabetes prevention.

February 16, 2011

French drug maker Sanofi-Aventis will acquire U.S. biotech giant Genzyme for $20.1 billion, under an agreement the two companies announced Wednesday.

CAMBRIDGE, Mass. — French drug maker Sanofi-Aventis will acquire U.S. biotech giant Genzyme for $20.1 billion, under an agreement the two companies announced Wednesday.

February 3, 2011

Chauncey Billups, point guard for the NBA's Denver Nuggets team, was named the latest spokesman for a national multimedia campaign designed to educate preteens, teens and their parents about the importance of vaccination against serious, potentially life-threatening diseases.

NEW YORK — Chauncey Billups, point guard for the NBA's Denver Nuggets team, was named the latest spokesman for a national multimedia campaign designed to educate preteens, teens and their parents about the importance of vaccination against serious, potentially life-threatening diseases.

As the latest spokesman for Vaccine for Teens, Billups will be featured in a new public service announcement, which will air on NBA media and network/cable game broadcasts.

February 1, 2011

A federal court has lifted an injunction that had prevented drug maker Dr. Reddy’s Labs from marketing a generic version of an allergy drug.

HYDERABAD, India — A federal court has lifted an injunction that had prevented drug maker Dr. Reddy’s Labs from marketing a generic version of an allergy drug.

Dr. Reddy’s said the U.S. District Court of New Jersey had filed a stipulation and order lifting the earlier injunction against the drug maker regarding the selling of a version of fexofenadine hydrochloride and pseudoephedrine hydrochloride tablets in the 180-mg/240-mg strength. The drug is a generic version of Sanofi-Aventis’ and Albany Molecular Research’s Allegra-D 24.

January 28, 2011

Though Schering-Plough’s — now Merck’s — Claritin and Johnson & Johnson’s Zyrtec product lines have dominated the over-the-counter antihistamine market, the big share of the prescription antihistamine market held by Sanofi-Aventis’ Allegra (fexofenadine hydrochloride) could give it a battering ram to bust in as well, thanks to the big break Sanofi got in the form of a Food and Drug Administration approval of an OTC switch for the drug.

WHAT IT MEANS AND WHY IT'S IMPORTANT — Though Schering-Plough’s — now Merck’s — Claritin and Johnson & Johnson’s Zyrtec product lines have dominated the over-the-counter antihistamine market, the big share of the prescription antihistamine market held by Sanofi-Aventis’ Allegra (fexofenadine hydrochloride) could give it a battering ram to bust in as well, thanks to the big break Sanofi got in the form of a Food and Drug Administration approval of an OTC switch for the drug.

January 25, 2011

Sanofi-Aventis and its U.S. consumer healthcare division Chattem on Tuesday afternoon announced the Food and Drug Administration has approved the Allegra (fexofenadine HCl) family of allergy medication products for over-the-counter use in adults and children 2 years of age and older.

PARIS — Sanofi-Aventis and its U.S. consumer healthcare division Chattem on Tuesday afternoon announced the Food and Drug Administration has approved the Allegra (fexofenadine HCl) family of allergy medication products for over-the-counter use in adults and children 2 years of age and older.

Products will be on store shelves in March, the companies announced.

January 20, 2011

Finalizing an acquisition of biotech company Genzyme by French drug maker Sanofi-Aventis “will take some time,” media reports quoted Genzyme’s chief executive as saying.

BOSTON — Finalizing an acquisition of biotech company Genzyme by French drug maker Sanofi-Aventis “will take some time,” media reports quoted Genzyme’s chief executive as saying.

The Boston Globe quoted Genzyme CEO Henri Termeer as saying it would be a long process to understand the company’s full value, in particular because of an investigational multiple sclerosis drug, Campath (alemtuzumab), which could achieve blockbuster sales and thus raise the company’s value and acquisition price if it wins approval.

January 14, 2011

The Food and Drug Administration and drug maker Sanofi-Aventis are warning healthcare professionals and patients about the possibility of severe liver injury in patients taking a Sanofi heart drug.

SILVER SPRING, Md. — The Food and Drug Administration and drug maker Sanofi-Aventis are warning healthcare professionals and patients about the possibility of severe liver injury in patients taking a Sanofi heart drug.